Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02271854 · ClinicalTrials.gov registry record · Phase 3
A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT02271854 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 102 participants.
The verdict
NCT02271854, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with DOMS
Interventions
- DRUG Placebo
- DRUG Diclofenac sodium gel 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2014-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02271854
The ClinicalTrials.gov registry entry for NCT02271854 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02271854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02271854 about?
NCT02271854 is a clinical study titled "A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness". This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with DOMS
What is the current status of trial NCT02271854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2014-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02271854?
The interventions under investigation include: Placebo (DRUG), Diclofenac sodium gel 1% (DRUG).
Who is sponsoring clinical trial NCT02271854?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.